Clinical trial NCT03108443: Novel Markers for Detecting Early Progression of Glaucoma
Official title: Novel Markers for Detecting Early Progression of Glaucoma
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Glaucoma
Lead sponsor: Nova Scotia Health Authority
Sponsor class: OTHER
First posted: 2017-04-11
Enrollment: 250
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Glaucoma patients recruited from a Primary Care Clinic Healthy control subjects recruited from the general population

Brief summary: Current methods of detecting glaucoma and monitoring its progression over time involve visual assessment of the optic nerve, thickness measurements of nerve tissue in the eye (using optical coherence tomography, OCT) as well as functional tests which measure peripheral, or side, vision. The objective of this study is to determine if a new technique of measuring blood flow in the eye, using OCT, can be used to better detect and/or monitor changes in glaucoma patients and suspects than these methods.

Detailed description: Changes in the superficial optic nerve head (ONH) surface and loss of retinal nerve fibre layer (RNFL) thickness detected with clinical imaging are predictive of future visual field loss. Imaging of the deep ONH, the likely origin of glaucomatous damage, represents the next logical next step, but has eluded clinicians because of the lack of capable technology.

New advances in optical coherence tomography (OCT) imaging now offer an exciting opportunity to close the gap between the histomorphometric knowledge on deep ONH changes gained with research in experimental monkey glaucoma and imaging in clinical glaucoma.

There is compelling evidence that gross ONH and retinal hemodynamic changes are functional indicators of glaucoma progression. Accurate tracking of blood flow in the ONH is a logical step, but has evaded researchers for several reasons including the highly reflective ONH tissue which variably inhibits signal penetration making the complex nature of retinal and posterior ciliary contributions to ONH flow difficult to segregate. Even though glaucoma damage originates in the ONH, retinal ganglion cell (RGC) axons may show the earliest functional alterations as they have high metabolic demand and vulnerability to damage. Therefore, tracking blood flow in the RNFL, which is highly segmental and resolvable, could be a better and more sensitive approach compared to that in the ONH. The macula contains almost 50% of the entire RGC population; likewise, monitoring blood flow in the macular inner vascular plexus corresponding to the ganglion cell layer (GCL) is likely to be highly informative for glaucoma progression. OCT based angiography (OCTA), which maps vessel density in different retinal vascular beds with unparalleled axial resolution, will finally allow us to quantify highly localized parameters related to blood flow and identify patients with higher progression risk. Current data analysis of progression detection based on inter-subject or population-based variability models are inefficient, leading to false-positive and false-negative results. Innovative data analysis techniques that build accurate models of intra-subject variability will add cumulative value to the novel imaging markers for progression.

Eligibility criteria: Glaucoma Group

Inclusion Criteria:

* visual acuity ≥ 6/12
* glaucomatous ONH change
* glaucomatous visual field loss with a positive Glaucoma Hemifield Test

Exclusion Criteria:

* non-glaucomatous ocular disease
* chronic systemic disease or treatment affecting the visual field
* refraction exceeding 6 D equivalent sphere or 3 D astigmatism
* inability to provide informed consent

Control Group

Inclusion Criteria:

* visual acuity ≥ 6/12
* normal eye examination with intraocular pressure ≤ 21 mm Hg
* normal visual field and negative Glaucoma Hemifield Test

Exclusion Criteria:

* chronic ocular disease
* chronic systemic disease or treatment affecting the visual field
* refraction exceeding 6 D equivalent sphere or 3 D astigmatism
* inability to provide informed consent

Primary outcomes:
measure: Blood flow
timeFrame: Changes over the 5 year course of the study
Secondary outcomes:
measure: Optic nerve head (ONH) anatomy
timeFrame: Changes over the 5 year course of the study
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: Eye Care Centre
state: Nova Scotia
Study officials:
affiliation: Nova Scotia Health Authority
name: Balwantray Chauhan, PHD
role: PRINCIPAL_INVESTIGATOR
References: